A PYMNTS Company

US: FTC wants more information on AbbVie-Allergan deal

By  |  September 29, 2019

The Federal Trade Commission (FTC) has made a request for additional information regarding AbbVie’s proposed US$63 billion purchase of Allergan, reported Reuters. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The deal, announced in June, would create a company with US$48.5 billion in combined revenue and a product line of more than 50 therapies, including AbbVie’s Humira, the best-selling drug in the world, and Allergan’s popular wrinkle-smoother Botox.

    North Chicago-based AbbVie and Dublin, Ireland-based Allergan are cooperating with the FTC and expect to close the transaction in early 2020, AbbVie said in a statement on Friday, September 27.

    The FTC’s request was issued under the Hart-Scott Rodino Antitrust Improvements Act of 1976, which requires large companies to file a report before completing a merger, the statement adds.

    Unions and other groups, including the American Federation of State, County and Municipal Employees, earlier this month asked the FTC to block the deal at a time when high drug costs are a hot-button issue. In a letter dated September 4, the groups expressed concern that the merger could “exacerbate anticompetitive patent practices.“

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.